Work

Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer

Year: 2014

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-014-0099-0

Authors: Maha Hussain, Michael A. Carducci, Susan Slovin, Jeremy Cetnar, Jiang Qian, Evelyn M. McKeegan, Marion Refici-Buhr, Brenda Chyla, Stacie P. Shepherd, Vincent L. Giranda, Joshi J. Alumkal

Institutions: University of Michigan, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, University of Wisconsin System, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, OHSU Knight Cancer Institute, AbbVie (United States), Oregon Health & Science University

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Award: G1165598027

OpenAlex ID: W2037352738

FWCI: 3.893

Cites: 42

Cited by: 97

Related to: 10